Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.

详细信息    查看全文

• 作者：Hiroshi Imaoka^a ; ^{hiroshi.imaoka.md@me.com" class="auth_mail" title="E-mail the corresponding author} ; Tadayuki Kou^b ; Masao Tanaka^c ; Shinichi Egawa^d ; Nobumasa Mizuno^a ; Susumu Hijioka^a ; Kazuo Hara^a ; Shujiro Yazumi^b ; Yasuhiro Shimizu^e ; Kenji Yamao^a
• 关键词：Elderly patients ; Pancreatic cancer ; Gemcitabine ; S-1 ; Subgroup analysis
• 刊名：European Journal of Cancer
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：54
• 期：Complete
• 页码：96-103
• 全文大小：434 K

文摘

<dl class="listitem" id="list_ulist0010"><dt class="label">•dt><dd>

d="p0010">We performed a subgroup analysis from a randomised phase III trial, the GEST study.

dd><dt class="label">•dt><dd>

d="p0015">Gemcitabine plus S-1 (GS), S-1, and gemcitabine treatment resulted in similar overall survival.

dd><dt class="label">•dt><dd>

d="p0020">Severe adverse haematological events were more frequent with GS treatment.

dd><dt class="label">•dt><dd>

d="p0025">Three treatment-related deaths were observed in elderly GS-treated patients.

dd>dl>